Document Detail

Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
MedLine Citation:
PMID:  18594989     Owner:  NLM     Status:  MEDLINE    
Ergot-derived dopamine receptor agonists, especially pergolide and cabergoline, have been associated with an increased risk of valvular heart disease in patients treated for Parkinson's disease. Cabergoline at lower doses than those employed in Parkinson's disease is widely used in patients with prolactinomas, because of its high efficacy and tolerability; however, its safety with regard to cardiac valve disease is unknown. In order to assess the prevalence of cardiac valve regurgitation in patients with prolactinomas treated with long-term cabergoline, we performed a prospective and multicentric study including four university centers in the province of Quebec. A transthoracic echocardiogram was performed in 70 patients with prolactinomas treated with cabergoline for at least 1 year (duration of treatment, 55 +/- 22 months; cumulative dose 282 +/- 271 mg, mean +/- SD) and 70 control subjects matched for age and sex. Valvular regurgitation was graded according to the American Society of Echocardiography recommendations as mild, moderate, or severe. Moderate valvular regurgitation was found in four patients (5.7%) and five control subjects (7.1%) (P = 0.73). No patient had severe valvular regurgitation. There was no correlation between the presence of significant heart-valve regurgitation and cabergoline cumulative dose, duration of cabergoline treatment, prior use of bromocriptine, age, adenoma size, or prolactin levels. Our results show that low doses of cabergoline seem to be a safe treatment of hyperprolactinemic patients. However, in patients with prolonged cabergoline treatment, we suggest that echocardiographic surveillance may be warranted.
Sophie Vallette; Karim Serri; Juan Rivera; Patricia Santagata; Sophie Delorme; Natasha Garfield; Nora Kahtani; Hugues Beauregard; Nahla Aris-Jilwan; Ghislaine Houde; Omar Serri
Related Documents :
11805959 - Echocardiographic correlates of freestyle stentless tissue aortic valve endocarditis.
17061609 - Repair of ebstein anomaly: early and mid-term results.
16048499 - Successful treatment with rfviia of spontaneous intracerebral hemorrhage in a patient w...
11451809 - Heimlich valve in the management of pneumothorax in patients with advanced aids.
2917099 - Abnormal cardiac signs after fontan type of operation: indicators of residua and sequelae.
17513209 - Predictive value of cardiothoracic ratio as a marker of severity of aortic regurgitatio...
10907799 - Thyroid function screening in acute geropsychiatric admissions.
3020179 - Recent progress on an endogenous digitalislike factor in hypertension.
1517489 - Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Pituitary     Volume:  12     ISSN:  1573-7403     ISO Abbreviation:  Pituitary     Publication Date:  2009  
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-10-20     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  United States    
Other Details:
Languages:  eng     Pagination:  153-7     Citation Subset:  IM    
Department of Endocrinology, Hôpital Notre-Dame, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montreal, QC, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Dopamine Agonists / adverse effects,  therapeutic use*
Ergolines / adverse effects,  therapeutic use*
Heart Valve Diseases / complications*
Middle Aged
Prolactinoma / complications*,  drug therapy*
Reg. No./Substance:
0/Dopamine Agonists; 0/Ergolines; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Jamaican bitter yam sapogenin: potential mechanisms of action in diabetes.
Next Document:  What are critical outcome measures for patients receiving pituitary replacement following brain inju...